Farnesoid X Receptor an Emerging Target to Combat Obesity

Digestive Diseases

Volumn 35, Issue 3, 2017, Pages 185-190

  Daniel De Magalhaes Filho, C ^a   Downes, Michael ^a   Evans, Ronald M ^a  

^a SALK INSTITUTE FOR BIOLOGICAL STUDIES   (United States)

Author keywords

Bile acids; Diabetes; Fexaramine; FXR; Obesity

Indexed keywords

CHENODEOXYCHOLIC ACID; CHOLIC ACID; CYTOCHROME P450; FARNESOID X RECEPTOR; LIVER RECEPTOR HOMOLOG 1; OCCLUDIN; BENZENE DERIVATIVE; BILE ACID; CELL RECEPTOR; FARNESOID X-ACTIVATED RECEPTOR; FEXARAMINE;

ARTICLE; DIABETES MELLITUS; DNA BINDING; GLUCOSE HOMEOSTASIS; GLUCOSE TOLERANCE; HEPATITIS; HEPATOMEGALY; INFLAMMATION; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID METABOLISM; MOUSE; NONHUMAN; OBESITY; OXYGEN CONSUMPTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; AGONISTS; ANIMAL; BIOSYNTHESIS; BLOOD; HUMAN; METABOLISM; MOLECULARLY TARGETED THERAPY;

ANIMALS; BENZENE DERIVATIVES; BILE ACIDS AND SALTS; HUMANS; MOLECULAR TARGETED THERAPY; OBESITY; RECEPTORS, CYTOPLASMIC AND NUCLEAR;

EID: 85014688842     PISSN: 02572753     EISSN: 14219875     Source Type: Journal    
DOI: 10.1159/000450909     Document Type: Article

References (49)

1. WHO: Factsheet on Obesity, 2016.
2. Wensveen FM, Valentić S, Šestan M, Turk Wensveen T, Polić B: The 'Big Bang' in obese fat: events initiating obesity-induced adipose tissue inflammation. Eur J Immunol 2015; 45: 2446-2456.
3. Boutens L, Stienstra R: Adipose tissue macrophages: going off track during obesity. Diabetologia 2016; 59: 879-894.
4. Falany CN, Johnson MR, Barnes S, Diasio RB: Glycine and taurine conjugation of bile acids by a single enzyme. Molecular cloning and expression of human liver bile acid CoA:amino acid N-acyltransferase. J Biol Chem 1994; 269: 19375-19379.
5. Kuipers F, Bloks VW, Groen AK: Beyond intestinal soap-bile acids in metabolic control. Nat Rev Endocrinol 2014; 10: 488-498.
6. Forman BM, et al: Identification of a nuclear receptor that is activated by farnesol metabolites. Cell 1995; 81: 687-693.
7. Makishima M, et al: Identification of a nuclear receptor for bile acids. Science 1999; 284: 1362-1365.
8. Parks DJ, et al: Bile acids: natural ligands for an orphan nuclear receptor. Science 1999; 284: 1365-1368.
9. Wang H, Chen J, Hollister K, Sowers LC, Forman BM: Endogenous bile acids are ligands for the nuclear receptor FXR/BAR. Mol Cell 1999; 3: 543-553.
10. Inagaki T, et al: Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metab 2005; 2: 217-225.
11. Kim I, et al: Differential regulation of bile acid homeostasis by the farnesoid X receptor in liver and intestine. J Lipid Res 2007; 48: 2664-2672.
12. Chen F, et al: Liver receptor homologue-1 mediates species-and cell line-specific bile aciddependent negative feedback regulation of the apical sodium-dependent bile acid transporter. J Biol Chem 2003; 278: 19909-19916.
13. Hwang ST, Urizar NL, Moore DD, Henning SJ: Bile acids regulate the ontogenic expression of ileal bile acid binding protein in the rat via the farnesoid X receptor. Gastroenterology 2002; 122: 1483-1492.
14. Boyer JL, et al: Upregulation of a basolateral FXR-dependent bile acid efflux transporter OSTalpha-OSTbeta in cholestasis in humans and rodents. Am J Physiol Gastrointest Liver physiol 2006; 290:G1124-G1130.
15. Parquet M, et al: Glucuronidation of bile acids in human liver, intestine and kidney. An in vitro study on hyodeoxycholic acid. FEBS Lett 1985; 189: 183-187.
16. Alnouti Y: Bile acid sulfation: a pathway of bile acid elimination and detoxification. Toxicol Sci 2009; 108: 225-246.
17. Marschall HU, et al: Fxr(-/-) mice adapt to biliary obstruction by enhanced phase I detoxification and renal elimination of bile acids. J Lipid Res 2006; 47: 582-592.
18. Sinal CJ, et al: Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis. Cell 2000; 102: 731-744.
19. Hanniman EA, Lambert G, McCarthy TC, Sinal CJ: Loss of functional farnesoid X receptor increases atherosclerotic lesions in apolipoprotein E-deficient mice. J Lipid Res 2005; 46: 2595-2604.
20. Duran-Sandoval, D, et al: Glucose regulates the expression of the farnesoid X receptor in liver. Diabetes 2004; 53: 890-898.
21. Duran-Sandoval D, et al: The farnesoid X receptor modulates hepatic carbohydrate metabolism during the fasting-refeeding transition. J Biol Chem 2005; 280: 29971-29979.
22. Zhang Y, et al: Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice. Proc Natl Acad Sci U S A 2006; 103: 1006-1011.
23. Cariou B, et al: The farnesoid X receptor modulates adiposity and peripheral insulin sensitivity in mice. J Biol Chem 2006; 281: 11039-11049.
24. Prawitt J, et al: Farnesoid X receptor deficiency improves glucose homeostasis in mouse models of obesity. Diabetes 2011; 60: 1861-1871.
25. Zhang Y, et al: Loss of FXR protects against diet-induced obesity and accelerates liver carcinogenesis in ob/ob mice. Mol Endocrinol 2012; 26: 272-280.
26. Kok T, et al: Enterohepatic circulation of bile salts in farnesoid X receptor-deficient mice: efficient intestinal bile salt absorption in the absence of ileal bile acid-binding protein. J Biol Chem 2003; 278: 41930-41937.
27. van Dijk TH, et al: An increased flux through the glucose 6-phosphate pool in enterocytes delays glucose absorption in Fxr-/-mice. J Biol Chem 2009; 284: 10315-10323.
28. Bjursell M, et al: Ageing Fxr deficient mice develop increased energy expenditure, improved glucose control and liver damage resembling NASH. PLoS One 2013; 8:e64721.
29. Maloney PR, et al: Identification of a chemical tool for the orphan nuclear receptor FXR. J Med Chem 2000; 43: 2971-2974.
30. Ma Y, Huang Y, Yan L, Gao M, Liu D: Synthetic FXR agonist GW4064 prevents diet-induced hepatic steatosis and insulin resistance. Pharm Res 2013; 30: 1447-1457.
31. Pellicciari R, et al: 6alpha-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity. J Med Chem 2002; 45: 3569-3572.
32. Fiorucci S, et al: Protective effects of 6-ethyl chenodeoxycholic acid, a farnesoid X receptor ligand, in estrogen-induced cholestasis. J Pharmacol Exp Ther 2005; 313: 604-612.
33. Liu Y, et al: Hepatoprotection by the farnesoid X receptor agonist GW4064 in rat models of intra-and extrahepatic cholestasis. J Clin Invest 2003; 112: 1678-1687.
34. Cipriani S, Mencarelli A, Palladino G, Fiorucci S: FXR activation reverses insulin resistance and lipid abnormalities and protects against liver steatosis in Zucker (fa/fa) obese rats. J Lipid Res 2010; 51: 771-784.
35. Trivedi PJ, Hirschfield GM, Gershwin ME: Obeticholic acid for the treatment of primary biliary cirrhosis. Expert Rev Clin Pharmacol 2016; 9: 13-26.
36. Mudaliar S, et al: Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease. Gastroenterology 2013; 145: 574-582.e1.
37. Adorini L, Pruzanski M, Shapiro D: Farnesoid X receptor targeting to treat nonalcoholic steatohepatitis. Drug Discov Today 2012; 17: 988-997.
38. Neuschwander-Tetri BA, et al: Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet 2015; 385: 956-965.
39. Hirschfield GM, et al: Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid. Gastroenterology 2015; 148: 751-761.e8.
40. Downes M, et al: A chemical, genetic, and structural analysis of the nuclear bile acid receptor FXR. Mol Cell 2003; 11: 1079-1092.
41. Fang S, et al: Intestinal FXR agonism promotes adipose tissue browning and reduces obesity and insulin resistance. Nat Med 2015; 21: 159-165.
42. Tomlinson E, et al: Transgenic mice expressing human fibroblast growth factor-19 display increased metabolic rate and decreased adiposity. Endocrinology 2002; 143: 1741-1747.
43. Fu L, et al: Fibroblast growth factor 19 increases metabolic rate and reverses dietary and leptin-deficient diabetes. Endocrinology 2004; 145: 2594-2603.
44. Potthoff MJ, et al: FGF15/19 regulates hepatic glucose metabolism by inhibiting the CREBPGC-1α pathway. Cell Metab 2011; 13: 729-738.
45. Modica S, et al: Selective activation of nuclear bile acid receptor FXR in the intestine protects mice against cholestasis. Gastroenterology 2012; 142: 355-365.e1-e4.
46. Inagaki T, et al: Regulation of antibacterial defense in the small intestine by the nuclear bile acid receptor. Proc Natl Acad Sci U S A 2006; 103: 3920-3925.
47. Gadaleta RM, et al: Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease. Gut 2011; 60: 463-472.
48. Berg RD: Bacterial translocation from the gastrointestinal tract. Trends Microbiol 1995; 3: 149-154.
49. Pournaras DJ, et al: The role of bile after Roux-en-Y gastric bypass in promoting weight loss and improving glycaemic control. Endocrinology 2012; 153: 3613-3619.